Annexon, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ANNX, updated each market day.
ANNX AI Sentiment
AI predicts Annexon, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Annexon, Inc. Common Stock
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Sector
Exchange
Market Cap
$985,312,404
Cap Tier
Employees
96
Headquarters
BRISBANE, CA
Listed Since
July 24, 2020
Website
ANNX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ANNX Volatility
Annexon, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
